Richard Mark Kirkner

Can Retina Candidates Find Their Place?

Where Can Emerging Retina Agents Find Their Place in Clinical Practice?

Few therapeutic areas in medicine have a drug pipeline as flush as retina’s, as shown by trial results of a dozen or more emerging therapies in the space presented at the American Academy of Ophthalmology and OIS@AAO 2018. The UK-based global analytics company GlobalData projects that sales within the age-related...

Read More
OIS@AAO Has a Record Year; So Does Ophthalmology Sector

OIS@AAO Has a Record Year; So Does Ophthalmology Sector

CHICAGO – A record crowd gathered for the 10th anniversary of OIS@AAO last week in Chicago, and one of the highlights is always the Year in Review delivered by OIS chairman Emmett Cunningham Jr., MD, PhD, MPH, who summarized “a banner year – a remarkable year really” for ophthalmology approvals...

Read More
The Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards

The Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards

The first Ophthalmology Innovation Awards were presented last night at the OIS-X Gala. Here’s a rundown of the award winners. Clinical Innovator: Ike Ahmed, MD Dr. Ahmed has been a leader in novel treatments for glaucoma, cataract, and lens implant surgery. His pioneering work in innovative glaucoma surgery includes coining...

Read More
YUTIQ Approval Latest Step in EyePoint’s Transformation

YUTIQ Approval Latest Step in EyePoint’s Transformation

The steroidal implant YUTIQ for treatment of chronic, noninfectious posterior uveitis is the second drug in EyePoint Pharmaceuticals’ ophthalmology portfolio to receive Food and Drug Administration approval this year – a signature accomplishment for an established pharma company let alone one that rebranded itself just seven months ago – but...

Read More
Preceyes Takes Robotic Surgery Platform, Trial Results to Euretina and AAO

Preceyes Takes Robotic Surgery Platform, Trial Results to Euretina and AAO

Netherlands-based Preceyes BV seems to have taken the lead in the race to develop a robotic platform for retinal surgery as it prepares to demonstrate its system this week at Euretina 2018 in Vienna and then report on results of the first trial of the robot in humans at the...

Read More
First US-Approved Nerve Growth Factor is for the Eye

First US-Approved Nerve Growth Factor is for the Eye

In the use of biological agents for treatment of eye disease, the back of the eye has been pretty much the sole domain thanks to the broad acceptance of anti-VEGF drugs for treatment of age-related macular degeneration, diabetic macular edema, and retinal vascular disorders, but the Italian biopharmaceutical firm Dompé...

Read More
Novartis’ Plans for Brolucizumab and Beyond

Novartis’ Guerard Shares Plans for Brolucizumab, Lucentis, Gene Therapy, and FocalView App

Coming off the positive feedback at the American Society of Retina Specialists meeting to trial results of the investigative anti-VEGF agent brolucizumab, Frederic Guerard, Novartis’ franchise head of ophthalmology, provides insight into his team’s strategy for bringing brolucizumab to market while keeping its global commitment to Lucentis, for which Novartis...

Read More
A Future Vision of Medicine from the Masters of Retina

A Future Vision of Medicine from the Masters of Retina

Two forces are emerging in healthcare that could determine how quickly personalized medicine takes over: an outcomes-based system that pays drug makers only when their treatments work; and more precise diagnostic technology that utilizes artificial intelligence and telemedicine to ensure a high probability that those treatments work. That was the...

Read More
After Trial Results, Allergan Set to Tweak Abcipar Formulation

After Trial Results, Allergan Set to Tweak Abcipar Formulation

Last week, one day before the American Society of Retina Specialists and OIS Retina convened in Vancouver, Allergan and its collaborative partner Molecular Partners touted the release of top-line results from two Phase III clinical trials showing its abcipar pegol DARPin drug met its primary endpoint – noninferiority to ranibizumab...

Read More
FFB Showcase an OIS Retina Can’t-Miss

Here’s What You’ll Learn at OIS Retina’s Emerging Science Session

OIS Retina, set to kick off next Friday, July 20, when the annual meeting of the American Society of Retina Specialists (ASRS) starts in Vancouver, will have a new wrinkle this year: the Foundation Fighting Blindness (FFB) Emerging Science Showcase. Representatives of three companies and one research lab will explore...

Read More
What’s Next for Alcon Spin-off

What’s Next for Alcon Spin-off

As Novartis unveiled plans to spin off its Alcon eye care unit, the Swiss healthcare giant named Alcon CEO Mike Ball chairman-designate to guide the transformation of the Fort Worth, TX-based unit into a Swiss-based global device company. How much will the spin-off bring in? In the announcement, Novartis also...

Read More
Anti-VEGF Biosimilars Target a Shifting Market

Anti-VEGF Biosimilars Target a Shifting Market

Developers of FYB201 may be getting a leg up in the race for a Lucentis biosimilar with the publication of interim results that confirm the efficacy of the candidate for monthly treatment of neovascular age-related macular degeneration (nAMD), with plans to bring it to market in 2020. However, a new...

Read More